Decision: Favourable

Study Title:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Plati

  • NREC Code:

    21-NREC-CT-070

  • Decision:

    Favourable

  • Meeting Date:

    01/09/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Dearbhaile Collins

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    GlaxoSmithKline

Scroll to Top
Skip to content